Display options
Cite
Ly KI, Crew LL, Graham CA, et al. Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. Oncol Lett. 2016;11(5):3471-3476doi: 10.3892/ol.2016.4393.
Ly, K. I., Crew, L. L., Graham, C. A., & Mrugala, M. M. (2016). Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. Oncology letters, 11(5), 3471-3476. https://doi.org/10.3892/ol.2016.4393
Ly, K Ina, et al. "Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience." Oncology letters vol. 11,5 (2016): 3471-3476. doi: https://doi.org/10.3892/ol.2016.4393
Ly KI, Crew LL, Graham CA, Mrugala MM. Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. Oncol Lett. 2016 May;11(5):3471-3476. doi: 10.3892/ol.2016.4393. Epub 2016 Mar 30. PMID: 27123138; PMCID: PMC4840907.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2016 May;11(5):3471-3476. doi: 10.3892/ol.2016.4393. Epub 2016 Mar 30.

Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience.

Oncology letters

K Ina Ly, Laura L Crew, Carrie A Graham, Maciej M Mrugala

Affiliations

  1. Department of Neurology, University of Washington Medical Centre, Seattle, WA 98195, USA.
  2. Department of Neurological Surgery, University of Washington Medical Centre, Seattle, WA 98195, USA.
  3. Department of Neurology, University of Washington Medical Centre, Seattle, WA 98195, USA; Department of Neurological Surgery, University of Washington Medical Centre, Seattle, WA 98195, USA; Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

PMID: 27123138 PMCID: PMC4840907 DOI: 10.3892/ol.2016.4393

Abstract

Rituximab (RTX) improves the outcome in patients with systemic diffuse large B-cell lymphoma (DLBCL), but its benefit in primary central nervous system lymphoma (PCNSL) is unclear. In the present study, a single-institution retrospective analysis was performed for 12 patients with newly diagnosed PCNSL treated with combined high-dose methotrexate (HD-MTX) and RTX. MTX was administered biweekly at 8 g/m

Keywords: high-dose methotrexate; non-Hodgkin's lymphoma; primary central nervous system lymphoma; rituximab

References

  1. J Clin Oncol. 1997 Oct;15(10):3266-74 - PubMed
  2. Clin Cancer Res. 2012 Feb 15;18(4):1146-55 - PubMed
  3. Ann Oncol. 2009 Feb;20(2):319-25 - PubMed
  4. Nat Rev Neurol. 2013 Jun;9(6):317-27 - PubMed
  5. J Clin Oncol. 2006 Oct 1;24(28):4570-4 - PubMed
  6. J Clin Oncol. 1992 Apr;10(4):635-43 - PubMed
  7. Arch Neurol. 2010 Mar;67(3):291-7 - PubMed
  8. Cancer. 2004 Jul 1;101(1):139-45 - PubMed
  9. Neurology. 2014 Jul 15;83(3):235-9 - PubMed
  10. Neurology. 2004 Sep 14;63(5):901-3 - PubMed
  11. J Hematol Oncol. 2012 Oct 11;5:64 - PubMed
  12. Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 - PubMed
  13. Arch Neurol. 2005 Oct;62(10):1595-600 - PubMed
  14. Ann Oncol. 2000 Mar;11(3):374-5 - PubMed
  15. Radiother Oncol. 1997 Jun;43(3):247-52 - PubMed
  16. Ann Neurol. 2002 Feb;51(2):247-52 - PubMed
  17. Lancet. 2009 Oct 31;374(9700):1512-20 - PubMed
  18. Cancer. 2000 Sep 15;89(6):1359-70 - PubMed
  19. J Clin Oncol. 2003 Mar 15;21(6):1044-9 - PubMed
  20. Br J Cancer. 2011 Oct 25;105(9):1414-8 - PubMed
  21. Neurology. 2011 Mar 8;76(10):929-30 - PubMed
  22. J Clin Oncol. 1998 Mar;16(3):859-63 - PubMed
  23. Neuro Oncol. 2010 Jul;12(7):736-44 - PubMed
  24. Lancet Oncol. 2010 Nov;11(11):1036-47 - PubMed
  25. Lancet Neurol. 2009 Jun;8(6):581-92 - PubMed
  26. N Engl J Med. 2001 Aug 9;345(6):425-32 - PubMed
  27. J Neurooncol. 2012 Sep;109(2):285-91 - PubMed
  28. J Clin Oncol. 2007 Oct 20;25(30):4730-5 - PubMed
  29. Ann Oncol. 2011 Sep;22(9):2080-5 - PubMed

Publication Types